دورية أكاديمية
أعرض في EDS

Bio-diagnostic performances of microRNAs set related to DNA damage response pathway among hepatitis C virus-associated hepatocellular carcinoma patients.

التفاصيل البيبلوغرافية
العنوان: Bio-diagnostic performances of microRNAs set related to DNA damage response pathway among hepatitis C virus-associated hepatocellular carcinoma patients.
المؤلفون: Abdo SM; Biochemistry Division, Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt. Sara.Mohamed@science.helwan.edu.eg., Shousha WG; Biochemistry Division, Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt., Mohamed AA; Biochemistry Department, National Hepatology and Tropical Medicine Research Institute, Cairo University, Cairo, Egypt., Elshobaky M; Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt., Saleh M; Internal Medicine department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt., Ali MMA; Biochemistry Division, Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.
المصدر: Journal, genetic engineering & biotechnology [J Genet Eng Biotechnol] 2023 Aug 17; Vol. 21 (1), pp. 85. Date of Electronic Publication: 2023 Aug 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101317150 Publication Model: Electronic Cited Medium: Internet ISSN: 2090-5920 (Electronic) Linking ISSN: 1687157X NLM ISO Abbreviation: J Genet Eng Biotechnol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2024- : [Amsterdam, Netherlands] : Elsevier B.V.
Original Publication: [Cairo] : Academy of Scientific Research and Technology, Information and Scientific Services Sector, National Information and Documentation Center
مستخلص: Background: Up to date, a well-defined microRNAs (miRNAs) profile involved in hepatocellular carcinoma (HCC) pathogenesis remains indecisive. Thus, employing miRNAs for HCC diagnosis is demanded for early therapeutic interventions. We aimed to evaluate the usage of miRNAs set related to the SuperPath: miRNAs involved in DNA damage response pathway as effective biomarkers for HCV-related HCC diagnosis.
Results: The study enrolled 97 patients with HCV-related HCC, 84 with hepatitis C virus (HCV), 97 with liver cirrhosis (LC), and 84 healthy individuals. Serum miRNA-23a, miRNA-203, miRNA-100-5p, and miRNA-16 were quantified using qRT-PCR experiments, AFP and routine LFTs were estimated via standard techniques. Pathway enrichment analysis along with the construction of miRNAs regulatory network were performed. With respect to healthy individuals, miRNA-203, miRNA-100-5p, and miRNA-16 were significantly downregulated in HCC, HCV, and LC groups, while miRNA-23a showed significant upregulation (p < 0.001). miRNAs exhibited significant correlations with AFP, ALT, AST, and albumin. Also, elevated levels of miRNA-23a were recognized in patients with multiple focal lesions and/or lesion size > 5 cm. Additionally, the diagnostic performance of miRNA-23a expression level at a selected cut-off value of 3.99 overtakes AFP, while expressions of miR-203, miRNA-100-5p, and miRNA-16 represent poor diagnostic outcomes.
Conclusions: Keeping in mind the individual variability and high level of heterogeneity in HCC, our data revealed the diagnostic value of miRNA-23a expression in HCV-related HCC patients. Further extra in silico HCC-specific microRNAs sets are demanded in diagnosis.
(© 2023. Academy of Scientific Research and Technology.)
References: Med Oncol. 2012 Sep;29(3):1859-65. (PMID: 21786180)
Arch Med Sci. 2019 Oct;15(6):1454-1461. (PMID: 31749873)
Oncol Rep. 2016 Aug;36(2):633-40. (PMID: 27279136)
Prog Mol Biol Transl Sci. 2019;162:199-212. (PMID: 30905450)
Cell Biochem Funct. 2013 Jan;31(1):82-5. (PMID: 22886454)
Mol Diagn Ther. 2018 Apr;22(2):179-201. (PMID: 29388067)
Arch Virol. 2015 Aug;160(8):2043-50. (PMID: 26071245)
Cancers (Basel). 2021 Jan 29;13(3):. (PMID: 33572780)
Sci Rep. 2019 Jul 18;9(1):10464. (PMID: 31320713)
Transl Oncol. 2017 Feb;10(1):22-32. (PMID: 27888710)
PLoS Genet. 2017 Jul 13;13(7):e1006887. (PMID: 28704388)
Cancers (Basel). 2018 Dec 20;11(1):. (PMID: 30577536)
Int J Environ Res Public Health. 2022 Mar 31;19(7):. (PMID: 35409839)
PLoS One. 2019 Feb 5;14(2):e0211581. (PMID: 30721267)
Oncol Lett. 2019 Dec;18(6):6126-6142. (PMID: 31788087)
Cell Physiol Biochem. 2015;37(6):2143-59. (PMID: 26606597)
Mol Diagn Ther. 2015 Aug;19(4):213-20. (PMID: 26133725)
PLoS One. 2019 Sep 12;14(9):e0216847. (PMID: 31513595)
Methods Mol Biol. 2022;2257:375-422. (PMID: 34432288)
Nat Genet. 2002 Aug;31(4):339-46. (PMID: 12149612)
Contemp Oncol (Pozn). 2016;20(1):20-7. (PMID: 27095935)
Hepatology. 2013 Feb;57(2):840-7. (PMID: 23081718)
Hepatology. 2008 Apr;47(4):1223-32. (PMID: 18307259)
World J Gastroenterol. 2009 Apr 14;15(14):1665-72. (PMID: 19360909)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
J Clin Gastroenterol. 2011 Apr;45(4):355-60. (PMID: 21278583)
Br J Surg. 1973 Aug;60(8):646-9. (PMID: 4541913)
Oncotarget. 2016 Dec 20;7(51):84017-84029. (PMID: 27705947)
Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):318-30. (PMID: 24417970)
Hepatology. 2012 Jul;56(1):186-97. (PMID: 22318941)
Cancer. 1985 Aug 15;56(4):918-28. (PMID: 2990661)
Cancer Cell Int. 2015 Jun 18;15:62. (PMID: 26109910)
Mol Cell Biochem. 2013 Nov;383(1-2):49-58. (PMID: 23842624)
Cancer Res. 2010 Dec 1;70(23):9798-807. (PMID: 21098710)
فهرسة مساهمة: Keywords: AFP; HCC,HCV-related HCC; In silico HCC-microRNAs; Serum biomarkers; miRNA-100-5p; miRNA-16; miRNA-203; miRNA-23a
تواريخ الأحداث: Date Created: 20230816 Latest Revision: 20231121
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10432369
DOI: 10.1186/s43141-023-00537-2
PMID: 37587273
قاعدة البيانات: MEDLINE
الوصف
تدمد:2090-5920
DOI:10.1186/s43141-023-00537-2